Key Highlights

  • The third-quarter net loss widened to USD 40.2 million, or USD 0.84 per share, from USD 26.9 million, or USD 0.71 per share, twelve months earlier.
  • Research and development spending increased to USD 34.3 million from USD 22.3 million, and selling, general and administrative costs reached USD 9.8 million against USD 7.7 million.
  • Cash, cash equivalents and short-term investments totaled USD 395.0 million at September 30, 2026, before October financings with combined net proceeds of about USD 410.7 million (calculated).
  • A Phase 2 bipolar mania trial of RAP-219 met its primary endpoint, showing a 3.1-point improvement over placebo with a p-value of 0.045.

Operating Costs Rise as Two Epilepsy Studies Enroll

Rapport Therapeutics (NASDAQ:RAPP) is a clinical-stage biotechnology firm building small molecule precision medicines for neurological and psychiatric disorders. It submitted its Quarterly Report on November 4, 2026, covering the period ended September 30, 2026. The net loss reached USD 40.2 million against USD 26.9 million, while operating expenses climbed to USD 44.1 million from USD 30.0 million. The lead candidate, RAP-219, is being tested in two parallel Phase 3 trials, FOCUS 1 and FOCUS 2, in drug-resistant focal onset seizures, and those studies began in the second quarter of 2026. Over nine months the net loss totaled USD 116.7 million versus USD 77.7 million, and collaboration Revenue of USD 20.0 million came from an upfront license payment, with none booked in the third quarter.

October Equity and Convertible Notes Add Capital

Financings closed on October 30, 2026, after quarter end. They comprised 9,761,905 shares at USD 21.00 plus pre-funded warrants, USD 172.5 million of 2.25% convertible senior notes due 2032, and a concurrent private Placement of 1,428,571 shares. Net proceeds came to approximately USD 215.7 million, USD 166.8 million and USD 28.2 million, respectively. The notes start with a conversion price near USD 26.78 per share, a 27.5% premium to the offering price, and may be settled in cash, stock or a mix. The company also sold 399,201 shares through its at-the-market program for about USD 10 million. New shares dilute current holders, and the notes add a fixed interest obligation.

Bipolar Mania Results and the Regulatory Calendar

In October 2026, the company reported that RAP-219 produced a statistically significant 3.1-point least squares mean improvement over placebo on the Young Mania Rating Scale at Week 3, with mean reductions of 15.4 and 12.3 points. The drug was generally well tolerated and no serious adverse events were reported. A meeting with the FDA is scheduled for the first quarter of 2027, and two Phase 3 trials in acute mania are expected to begin in the second half of 2027. A Phase 3 trial in generalized seizures is planned for the first half of 2027.

Where Things Stand

Partly. The October financings brought in about USD 410.7 million net (calculated), roughly matching the cash held at September 30, which gives Rapport Therapeutics (NASDAQ:RAPP) funding for two late-stage epilepsy trials. Spending is rising quickly, with a USD 40.2 million quarterly loss, so the new Capital is being consumed. The mania data add a second indication, and the first-quarter 2027 FDA meeting is the next marker.